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Helicobacter pylori (H. pylori)-associated gastritis is one of the most common infectious diseases in the United States,
China and worldwide. Gastric mucosa-associated tissue lymphoma (MALT lymphoma) is a rare mature B-cell
neoplasm associated with H. pylori infection that is curable by antibiotics therapy alone. The pathological
diagnosis of gastric MALT lymphoma can be reached by histological examination, immunohistochemical staining and
B-cell clonality analysis. H. pylori eradication is the choice of therapy for early-stage gastric MALT lymphoma. High
response rates and long-term survival have been reported in refractory and localized diseases treated with low-dose
radiation therapy. Systemic chemotherapy is recommended for advanced-stage gastric MALT lymphoma and cases
with large B-cell lymphoma transformation. Recent advances in the pathological diagnosis and management of gastric
MALT lymphoma are reviewed in this article.
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Helicobacter pylori (H. pylori) infection of the stomach
is one of the most common diseases worldwide. Accord-
ing to the World Health Organization, H. pylori infec-
tion contributes to approximately 75 % of stomach
cancers and 5.5 % of all cancers worldwide [1]. The in-
fection rate varies in different countries of the world and
also in different regions of China, from 55 to 80 % in the
mainland to 15 % in Hong Kong and 40 % in Taiwan
[2–4]. The infection rate is higher in rural areas than in
cities [4]. Gastric mucosa-associated lymphoid tissue
(MALT) lymphoma is a clonal B-cell neoplasm arising
from post-germinal center B-cells in the marginal zone
of the lymphoid follicles. H. pylori was identified from
the gastric mucosa of patients with active chronic gastri-
tis more than 30 years ago by Marshall and Warren [5].
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association of H. pylori gastritis with gastric MALT
lymphoma [6], extensive basic studies and clinical trials
have been performed worldwide, and treatment guide-
lines have been recommended for H. pylori-associated
gastritis and gastric MALT lymphoma [7–11]. Gastric
MALT lymphoma is a rare disease. The estimated inci-
dence of gastric lymphoma was approximately 0.3–0.8
per 100,000 people in Europe [8]. The incidence of
gastric MALT lymphoma was approximately 0.38 per
100,000 people in the United States, according to a re-
cent study. The incidence rates increased with age [12].
No population-based studies have been reported in the
Chinese literature, and the incidence of gastric MALT
lymphoma is unknown in China. We searched literature
of studies of H. pylori gastritis and gastric MALT lymph-
oma in English and Chinese and reviewed the recent
advances in the diagnosis and management of these two
closely related diseases. Current issues in the diagnosis
and management of the disease are also discussed.le is distributed under the terms of the Creative Commons Attribution 4.0
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ive appropriate credit to the original author(s) and the source, provide a link to
changes were made. The Creative Commons Public Domain Dedication waiver
ro/1.0/) applies to the data made available in this article, unless otherwise stated.
Hu et al. Biomarker Research  (2016) 4:15 Page 2 of 9Diagnosis of gastric MALT lymphoma
The diagnosis of gastric MALT lymphoma relies on clin-
ical symptoms, endoscopic features and pathohistological
examination of gastric biopsy tissue, as well as noninvasive
tests for H. pylori infection, such as the 13C-urea breath
test and the monoclonal stool antigen test. The clinical
presentation of patients with gastric MALT lymphoma is
nonspecific. The symptoms include dyspepsia, vague epi-
gastric pain, bloating and heartburn; more severe and
alarming symptoms are anemia, melena, hematemesis,
vomiting and weight loss.
Endoscopic examination with biopsy and histopatho-
logic examination is a standard practice in the diagnosis
of gastric MALT lymphoma in the United States and the
Western world. The macroscopic changes of the gastric
mucosa in MALT lymphoma are nonspecific, including
thickening of the mucosal folds, irregular nodules,
polypoid lesions, petechiae, edema, erosion and ulcers.
The distribution of the lesions is usually patchy, with
multiple foci. Therefore, sampling at different anatomic
sites is recommended during gastric endoscopic examin-
ation and biopsy. Biopsies should be taken from abnor-
mal and normal areas, including the antrum, the greater
and lesser curvatures, and the fundus. At least two biop-
sies should be taken from each site of the stomach, and
the tissue from each biopsy site should be fixed in separ-
ate containers with 10 % buffered formalin [13]. Sam-
pling from multiple sites may be difficult in practice as it
increases risk of complications, such as acute gastric
bleeding, especially in patients on anticoagulant therapy.
H. pylori-associated chronic active gastritis is present in
the majority of patients with gastric MALT lymphoma.
Histopathologic features of gastric MALT
lymphoma
Under microscopic examination, the biopsy tissue usu-
ally shows dense lymphoid infiltration with monotonous
features. Germinal centers may be observed with the
expansion of the marginal zone. The lymphoma cells are
typically small and monotonous with monocytoid fea-
tures, with small, round nuclei and a scant to moderate
amount of pink to clear cytoplasm. Some cases may
show prominent plasmacytoid differentiation mixed with
small lymphocytes. The lymphocytes may infiltrate the
glandular epithelium, resulting in the destruction of the
glands, forming so-called “lymphoepithelial lesions”. The
lymphocytes in the glands are B-cells, which may be
identified by immunohistochemical staining for B-cell
and epithelial markers such as CD20 and pan-
cytokeratin. However, these stains are not used routinely.
Common immunohistochemical stains may include the
B-cell markers CD20 and CD79a and the T-cell markers
CD3 and CD5. Staining for CD21 may be helpful to
highlight residual lymphoid follicles and expandingmarginal zones. Aberrant expression of CD43 by the B-
cells may be identified, which is a supporting evidence
for gastric MALT lymphoma. The diagnosis of gastric
lymphoma can be established by morphologic examin-
ation and immunohistochemical evaluation. However, a
majority of the cases may require clonality analysis of
the B-cells by in situ hybridization for kappa and lambda
light chains with formalin-fixed tissue sections. The ex-
pression of kappa/lambda light chain may be weak, and
they often cannot be detected by in situ hybridization.
Negative expression of the light chains cannot rule out
the diagnosis of lymphoma. If the result of in situ
hybridization is inconclusive, further molecular studies,
such as polymerase chain reaction (PCR), for immuno-
globulin heavy chain (IgH) gene rearrangement may be
beneficial. A definitive diagnosis of gastric MALT
lymphoma is supported if clonal IgH gene rearrange-
ment is demonstrated by a PCR study. However, this
result is not a prerequisite for the diagnosis of gastric
MALT lymphoma [14]. A report of “atypical lymphoid
proliferation, suspicious for MALT lymphoma” may be
issued for ambiguous cases. Clinical follow-up and re-
peat biopsy may finally lead to a definitive diagnosis.
Wotherspoon and colleagues [15] observed a spectrum
of histological changes between normal gastric mucosa,
chronic active gastritis and gastric MALT lymphoma, as
shown in Table 1. This histological grading is helpful in
differential diagnosis. Histopathologic changes of Types
3 and 4 requires immunohistologic staining and/or mo-
lecular investigation to reach a definitive diagnosis. The
biopsy tissues taken by endoscopy are usually small, and
the layer of muscularis propria may not be observed in
most of the biopsies. The depth of invasion of the gastric
wall by the lymphoma cells is important for disease sta-
ging, and it should be evaluated and documented if
identified under a microscope. Monotonous and dense
lymphoid infiltration in the gastric mucosa may raise the
suspicion of gastric MALT lymphoma. This requires the
pathologist’s experience and may be affected by the
adequacy of tissue processing, the thickness of the tissue
sectioning, and the quality of histologic staining. Immuno-
histochemical staining may show expansion of the B-cell
compartment with sheets of B-cells. The thickness of the
tissue sections can significantly affect the interpretation of
compartment expansion of B-cells or T-cells. The tissue
sections of the gastric biopsy should not be more than
3 μm in thickness. A false impression of mixed B-cell and
T-cell proliferation may be obtained due to inadequate
thickness of the tissue sections during immunostaining.
Gastric MALT lymphoma is a type of low-grade B-cell
lymphoma with tissue infiltration by small lymphocytes.
High-grade transformation to large B-cell lymphoma is
uncommon. If high-grade lymphoma is present, the infil-
tration of large lymphoma cells may be a predominant
Table 1 Wotherspoon scale of confidence of histological diagnosis of lymphoma [15]
Grade Description Histological features
0 Normal Scattered plasma cells in the lamina propria. No lymphoid follicles.
1 Chronic active gastritis Small clusters of lymphocytes in the lamina propria. No lymphoid follicles.
No LELs.
2 Chronic active gastritis with florid lymphoid follicle formation Prominent lymphoid follicles with surrounding mantle zone and plasma cells.
3 Suspicious lymphoid infiltrate, probably reactive Lymphoid follicles surrounded by CCL cells that infiltrate diffusely into the
lamina propria and occasionally into the epithelium.
4 Suspicious lymphoid infiltrate, probably lymphoma Lymphoid follicles surrounded by CCL cells that infiltrate diffusely into the
lamina propria and into the epithelium in small groups.
5 Low-grade B-cell lymphoma of MALT Presence of dense diffuse infiltrate of CCL cells in the lamina propria with
prominent lymphoepithelial lesions.
CCL cells centrocyte-like cells (or marginal zone cells), LEL lymphoepithelial lesion
Hu et al. Biomarker Research  (2016) 4:15 Page 3 of 9component or a minor component depending on the
stage of transformation. Identification of residual low-
grade components of MALT lymphoma may be helpful
for the differential diagnosis of large B-cell lymphoma
transformed from gastric MALT lymphoma versus pri-
mary diffuse large B-cell lymphoma or secondary stom-
ach involvement by diffuse large B-cell lymphoma
arising from other primary organs. Focal large B-cell
transformation of gastric MALT lymphoma is an un-
favorable prognostic feature and should be documented
in the pathology report when it presents [16–19].
The majority of gastric MALT lymphoma is associated
with H. pylori infection. H. pylori were reported in 50–
100 % of Chinese patients with gastric MALT lymphoma
[20–22]. Similar observations were also reported in
other areas of the world [23]. Searching for H. pylori is
recommended in routine H&E slides of gastric biopsies,
and the status of H. pylori should be documented in the
pathology report. Immunostaining for H. pylori on tissue
sections appears to be the most specific and sensitive
and should be performed whenever available (Fig. 1).
We found that immunostaining saved the pathologist’s
time while searching for the microorganisms under the
microscope due to the unambiguous features of the
staining (personal observation), although Giemsa and
Alcian blue stains also serve well as alternative stains
with high sensitivity and specificity [24]. Patients with
gastric MALT lymphoma positive for H. pylori have
better responses to antibiotics eradication therapy. The
persistence of H. pylori in gastric biopsies after antibi-
otics eradication therapy usually indicates reinfection or
the development of bacteria species resistant to the anti-
biotics. Therefore, a change in the therapeutic protocol
is recommended [25].
Molecular cytogenetic findings of gastric MALT
lymphoma
Many factors potentially affect the responsiveness of gas-
tric MALT lymphoma to H. pylori eradication therapy. A
balanced chromosomal translocation, t(11; 18)(q21;q21),results in a API2/MALT1 fusion gene, which is functional
in activating the nuclear factor kappa B pathway and is
associated with the pathogenesis of gastric MALT lymph-
oma. During translocation t(11;18)(q21;q21), the N-
terminal region of API2 fuses to the C-terminal region of
the MALT1 gene. Multiple breakpoints were identified in
exons 7 and 8 of the API2 gene, and 3 major breakpoints
were identified in the MALT1 gene. This cytogenetic ab-
normality could be demonstrated in approximately 20 %
of gastric MALT lymphomas of Chinese patients, ranging
from 14 to 22 % [26, 27]. The patients negative for trans-
location t(11; 18)(q21;q21) showed a higher response rate
than those positive for the translocation (78 % versus
22 %); higher median survival time was also observed
in the negative cases [18, 26]. Therefore, the status of
t(11; 18)(q21;q21) with the lymphoma is a strong pre-
dictor for therapeutic response and patient prognosis.
Interphase fluorescence in situ hybridization (FISH)
may be performed using dual-color break-apart API2
and MALT1 probes or a dual-color dual-fusion probe.
The test is highly sensitive and specific. Therefore,
FISH for t(11; 18)(q21;q21) on formalin-fixed tissue
sections should be performed routinely in newly diag-
nosed patients. Reverse transcriptase polymerase chain
reaction (RT-PCR) was designed to detect the mRNA
transcript of the API2/MALT1 fusion gene with high
sensitivity and specificity. RT-PCR can be performed
with tissue sections of paraffin-embedded, formalin-
fixed tissue block. However, more tissue sections are
required for the PCR reaction than for a FISH study.
Other genetic abnormalities observed in gastric
MALT lymphoma include translocations t(14;18)/IgH-
MALT1, t(1;14)/BCL10-IgH and t(3;14)/FOXP1-IgH.
However, these translocations are uncommon and
their clinical significance has not been defined. There-
fore, routine testing is not recommended [14].
The most common differential diagnosis of gastric
MALT lymphoma is severe chronic gastritis. Careful
morphologic examination of hematoxylin and eosin-
stained biopsy tissue sections is essential for differential
Fig. 1 Gastric biopsy showing intra-lamina small lymphocyte infiltrate with monotonous features (a, original magnification 100 X); foci of
lymphoepithelial lesion (b, H&E, original magnification 200 X); CD20 immunostaining shows sheets of CD20+ small B-cells (c, original
magnification 200 X); aberrant expression of CD43 is also detected (d, original magnification 200X). A repeat gastric biopsy 6 months after
H. pylori eradication showed scattered intra-lamina infiltrates of small lymphocytes, plasma cells and a few small loose lymphoid aggregates, indicating
complete remission (e, H&E, original magnification 100 X; f, 200 X)
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lymphoid infiltrates with mixed small lymphocytes and
plasma cells and a lack of lymphoepithelial lesions, and
it also appears more polymorphic. Immunostaining for
B-cell and T-cell markers, such as CD20, CD3 and
CD43, is helpful in difficult cases and may reveal well-Fig. 2 Gastric biopsy shows H. pylori-associated chronic active gastritis with sc
reactive germinal center and a slightly expanded marginal zone (a, H&E, origi
bacteria with curving configuration, characteristic of H. pylori (b, immunohistopreserved B-cell and T-cell compartments without evi-
dence of lymphoepithelial lesions (Fig. 2).
Molecular diagnosis of gastric MALT lymphoma
In some cases, the histopathologic features are uncertain.
Therefore, PCR for IgH gene rearrangement is helpful forattered small lymphocytes and plasma cells; a lymphoid follicle with a
nal magnification 100 X). Immunostaining of H. pylori shows intra-foveolar
chemical stain of H. pylori, original magnificantion 1000 X)
Table 2 Modified Ann Arbor (Musshoff) staging [25]
Modified Ann Arbor
system
Extension of organ involvement by lymphoma
I1E Mucosa, submucosa involvement
I2E Muscularis propria, serosa, neighboring organs
II1E Regional abdominal lymph nodes (compartment
I + II)
II2E Intra-abdominal distant lymph nodes
IIIE Extra-abdominal lymph nodes
IV Diffuse or disseminated infiltration of distant or
extra-gastrointestinal organs, bone marrow
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China have adapted PCR protocols for B-cell receptor
gene clonality analysis, which were originally developed by
European Biomed-2 Study Group [28]. The PCR for IgH
gene rearrangement covers a majority of B-cell lymph-
omas with high clinical sensitivity and specificity. Routine
testing for kappa light chain gene rearrangement is not
recommended. Multiple sets of PCR primers are designed
to detect more than 90 % cases of B-cell lymphomas.
Adequate positive and negative controls together with
patient specimens must be performed each time. The re-
sults of the controls should be included in the diagnostic
report of the PCR analysis. A result cannot be reported if
the control sample does not work or the DNA is disquali-
fied or suboptimal for the test. Clinical false-positive and
false-negative results have been reported in approximately
5–10 % of confirmed B-cell lymphoma cases. Therefore, it
is important to interpret the PCR results in combination
with histopathologic and immunophenotypic findings. A
more conservative approach to the diagnosis may be taken
for those atypical cases to avoid overdiagnosis and inter-
vention with aggressive therapy.
Summary of pathologic diagnostic points of
gastric MALT lymphoma
1. Infiltration of the gastric mucosa by dense,
monomorphic small lymphocytes.
2. Lymphoepithelial lesions.
3. Dense B-cell infiltrates with sheet formation
observed by immunohistochemical staining for
CD20 and CD79a with aberrant expression of
CD43.
4. H. pylori may be identified on hematoxylin
and eosin-stained slides and confirmed by
immunohistochemical staining.
5. In situ hybridization of the kappa and lambda light
chains on tissue sections may show monoclonal
light chain expression.
6. Monoclonal IgH gene rearrangement may be
detected by PCR using formalin-fixed tissue and
may be helpful in ambiguous cases.
7. API2/MALT1 gene rearrangement may be detected
in approximately 20 % of the cases by FISH.
Staging of gastric MALT lymphoma
As soon as a pathological diagnosis of gastric MALT
lymphoma is established, clinical staging of the disease
should be performed. The modified Ann Arbor (Mussh-
off ) system is recommended for the staging (Table 2)
[25]. The majority of cases with gastric MALT lymph-
oma are in the early stage of disease, with lymphoma
limited to the gastric mucosa, submucosa (stage I1E)
and less commonly, in the superficial layer of themuscularis propria (stage I2E). Endoscopic ultrasound
for the detection of lymphoma invasion of the stomach
wall has been used in European countries. Routine ab-
dominal CT scan is recommended for possible regional
gastric lymph node involvement (stage II1E). Bone mar-
row involvement is uncommon, and routine bone mar-
row biopsy for staging is not recommended for patients
with negative regional lymphadenopathy.
Management of gastric MALT lymphoma
Normal gastric mucosa lacks lymphoid aggregates; only
rare scattered lymphocytes, plasma cells and eosinophils
are identified in the gastric mucosa and submucosa. H.
pylori infection triggers an inflammatory reaction with
prominent neutrophil infiltration and lymphocytic prolif-
eration. The lymphoid cells form lymphoid follicles with
germinal center and minimal marginal zone expansion,
which is characteristic for H. pylori-associated chronic
active gastritis. The high prevalence of H. pylori infection
and low incidence of gastric MALT lymphoma among the
general population suggest that there is an interaction be-
tween H. pylori and host factors that determines the host
susceptibility to MALT lymphoma. This observation has
been supported by experimental studies. Certain genetic
predispositions have been identified [29, 30]. An increased
prevalence of both HLA-DQA1*0103 and HLA-
DQB1*0601 alleles and DQA1*0103-DQB1*0601 haplo-
types has been observed in patients with gastric MALT
lymphoma [29]. Due to the close association of H. pylori
with gastric MALT lymphoma, Wotherspoon, et al first
used antibiotics to treat patients with gastric MALT
lymphoma and induced dramatic regression of the lymph-
oma [6]. Since then, combined antibiotics for H. pylori
eradiation has become a standard therapy for patients
with gastric MALT lymphoma regardless of the status of
H. pylori in the biopsy tissue. The majority of H. pylori-
positive gastric MALT lymphomas are in early stage of
disease, with involvement of the gastric mucosa and sub-
mucosa (stage I1E); invasion of the muscularis propria
may be identified (stage I2E). Clinical studies have been
performed for eradiation therapy of H. pylori gastritis and
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Guidelines for the diagnosis and management of H. pylori
infection of the stomach were published and updated re-
cently by the World Gastroenterology Organization, the
American College of Gastroenterology, the Asian-Pacific
Association of Gastroenterology and other professional
organizations over the last decade (Table 3) [2, 7, 9, 11, 25,
31–36]. The guideline protocols are also adapted to H.
pylori eradication therapy in gastric MALT lymphoma. A
protocol combining a proton pump inhibitor (PPI) and
two antibiotics, or “triple therapy,” has been recom-
mended as first-line therapy until recently. However,
recent studies have shown an increase in drug resistance
to “triple therapy” in China and other areas of the world
[4, 33, 37]. Protocols with 14-day therapy appeared to have
a higher response rate than 7-day therapy without an
increase in side effects [9, 36]. Sequential therapy
showed an advantage over conventional “triple ther-
apy” and was recommended for the replacement of
conventional “triple therapy” as the first-line H. pylori
eradication therapy [38]. However, this result was not
confirmed by recent studies in China and other coun-
tries of the world [11, 39, 40].
Although patients with gastric MALT lymphoma with
no H. pylori are less responsive to H. pylori eradication,
a portion of the H. pylori-negative cases are potentially
curable by H. pylori eradication therapy alone [25]. The
rationale for this finding has not been elucidated. It is
suspected that some H. pylori-negative cases are false
negatives due to patchy distribution of the microorgan-
ism in the gastric mucosa and limited tissue sampling
during biopsy. PPI therapy before biopsy reduces the
sensitivity of H. pylori detection. Therefore, PPI should
be discontinued at least 2 weeks before H. pylori testing.Table 3 First-Line Regimens for Helicobacter pylori Eradication (ACG
Regimen Duration (da
Triple therapy: ∗Standard dose PPI b.i.d. (esomeprazole is q.d.),
clarithromycin 500 mg b.i.d., amoxicillin 1,000 mg b.i.d.
10–14
Triple therapy (penicillin allergic): Standard dose PPI b.i.d.,
clarithromycin 500 mg b.i.d., metronidazole 500 mg b.i.d.
10–14
Bismuth therapy: Bismuth subsalicylate 525 mg p.o. q.i.d.
metronidazole 250 mg p.o. q.i.d., tetracycline 500 mg p.o.
q.i.d., ranitidine 150 mg p.o. b.i.d. or standard dose PPI q.d.
to b.i.d.
10–14
Sequential therapy: PPI + amoxicillin 1 g b.i.d. ×5 followed
by: PPI, clarithromycin 500 mg, tinidazole 500 mg b.i.d. ×5
10
Note: The above recommended treatments are not all FDA approved. The FDA-app
Bismuth 525 mg q.i.d. + metronidazole 250 mg q.i.d. + tetracycline 500 mg q.i.d. ×
Lansoprazole 30 mg b.i.d. + clarithromycin 500 mg b.i.d. + amoxicillin 1 g b.i.d. × 10
Omeprazole 20 mg b.i.d. + clarithromycin 500 mg b.i.d. + amoxicillin 1 g b.i.d. × 10
Esomeprazole 40 mg q.d. + clarithromycin 500 mg b.i.d. + amoxicillin 1 g b.i.d. × 10
Rabeprazole 20 mg b.i.d. + clarithromycin 500 mg b.i.d. + amoxicillin 1 g b.i.d. × 7 d
ACG American College of Gastroenterology, PPI proton pump inhibitor, p.o. orally, q
∗ Standard dosages for PPIs are as follows: lansoprazole 30 mg p.o., omeprazole 20
40 mg p.oFollow-up examination was recommended in 3 months
after finishing H. pylori eradication therapy. Tests such
as the 13C urea breath test or the monoclonal stool anti-
gen test should be considered together with gastric
endoscopic examination and biopsy. The patient’s symp-
toms may disappear and H. pylori become undetectable
with a negative breath test if the therapy is effective. The
histological response usually lags behind the H. pylori
eradication, and a lymphoma infiltrate may persist for
12 months or even longer. Scattered small lymphocytes
and lymphoid aggregates may be identified with mild fi-
brosis (Fig. 2). The Groupe d’Etude des Lymphomes de
l’Adult (GELA) grading system was recommended for
the post-treatment evaluation of gastric MALT lymph-
oma (Table 4) [35, 38].
Immunohistochemical staining for B-cell and T-cell
markers is helpful for the examination. The subsequent
follow-up examinations may be arranged every 6 months
in the first year, and then the frequency may be reduced
to every 12 months. CT-scan or PCR study for IgH gene
rearrangement is generally not recommended during
follow-up.
If the above first-line therapy fails to eradicate H. pylori,
a second-line protocol should be considered. Increased
numbers of strains of H. pylori resistant to clarithromycin
and metronidazole have been reported during the last dec-
ade, ranging from 30 to 100 % [4, 33, 37]. “Quadruple
therapy” including PPI, bismuth, tetracycline and metro-
nidazole has been recommended [7]. The patient’s non-
compliance may be one of the most common reasons for
the failure of H. pylori eradication therapy. Discontinu-
ation of medicine is common as soon as patients experi-
ence relief of symptoms or unexpected side effects.
Therefore, patient education for therapy compliance isGuideline 2007) [7]
ys) Eradication Rates Comments
70–85 % Consider in non-penicillin-allergic patients who
have not previously received a macrolide
70–85 % Consider in penicillin-allergic patients who have
not previously received a macrolide or are unable
to tolerate bismuth quadruple therapy
75–90 % Consider in penicillin-allergic patients
>90 % Requires validation in North America
roved regimens are as follows:





.d. daily, b.i.d. twice daily, t.i.d. three times daily, q.i.d. four times daily
mg p.o., pantoprazole 40 mg p.o., rabeprazole 20 mg p.o., esomeprazole
Table 4 GELA grading system for post-treatment evaluation of gastric MALT lymphoma [35]
GELA category Histological features Clinical category
Complete histological response (CR) Total disappearance of lymphoid infiltrate with only scattered small
lymphocytes and plasma cells. Regressive stromal changes with
fibrosis and separation of glands can be observed.
Complete remission
Probable minimal residual disease (pMRD) Small lymphoid aggregates present, stromal regressive changes are
usually present.
Complete remission
Responding residual disease (rRD) Overt residual lymphoma with a nodular or diffuse infiltrate of
neoplastic B-cells but with clear evidence of regressive stromal
changes characterized by fine fibrosis and an “empty lamina
propria.”
Partial remission
No change (NC) Persistence of overt lymphoma identical to that observed at
diagnosis with no morphological features to suggest response
to treatment (such as stromal fibrosis).
Stable or progressive disease
GELA Groupe d’Etude des Lymphomes de l’Adult, MALT mucosa-associated lymphoid tissue
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peutic compliance if the first-line therapy fails before start-
ing the second-line therapy. Testing for drug sensitivity is
recommended when drug resistance is suspected. How-
ever, in clinical practice, a culture-based approach is
unfeasible, especially in the developing world and China.
Recently, point mutation analysis of H. pylori genes by
PCR, such as the 23S rRNA and gyrA genes, has been used
for assessing H. Pylori susceptibility to clarithromycin and
levofloxacin, respectively [41, 42]. Other factors may affect
the result of H. pylori eradication therapy and gastric
MALT lymphoma. Non-steroidal anti-inflammatory drugs
potentially affect the result of H. pylori eradication therapy.
H. pylori eradication therapy should be performed after the
discontinuation of non-steroidal anti-inflammatory drugs,
according to the Japanese Ministry of Health, Labor and
Welfare [43]. Tinidazole is an analogue of metronidazole
and has been used in the sequential therapy protocol for
H. pylori eradication. The inhibitory effect of tinidazole on
parasites, such as amoebae and bacteria is similar to metro-
nidazole. However, the side effects are more tolerable and
last a shorter time. The most common side effects include
nausea, bitter taste and itchiness. Drinking alcohol while
taking tinidazole may cause vomiting, headache, shortness
of breath, flushing and an increase in blood pressure.
Therefore, alcohol should be avoided during therapy with
tinidazole. Lower rates of drug resistance of H. pylori were
found with tinidazole than with metronidazole in a recent
in vitro study [2].
Primary gastric large B-cell lymphoma may be a de
novo large B-cell lymphoma or may be transformed
from gastric MALT lymphoma. Large B-cell lymph-
oma transformation from gastric MALT lymphoma is
uncommon, ranging from 0.5 % to 1 % in a 7-year
observation period [44, 45]. It is a more aggressive
lymphoma, and systematic chemotherapy is recom-
mended for the first-line treatment. However, the
current antibiotics protocols for H. pylori showedlimited side effects, and complete remission has been
observed in a portion of the patients with gastric
large B-cell lymphoma. Therefore, antibiotics therapy
may be beneficial for those cases with early-stage gas-
tric large B-cell lymphoma [16–19].
Radiation therapy is effective for patients with local-
ized gastric MALT lymphoma and is recommended for
patients who have early-stage disease and are refractory
to antibiotics therapy. The dosage of radiation has been
reduced over the last two decades. Wirth et al. reported
a study comprising 102 patients with gastric MALT
lymphoma, 58 previously untreated cases and 44 with
recurrent or residual disease after prior medical or surgi-
cal therapy. The overall 5-year recurrence-free survival
rate was 97 % with low doses of less than or equal to
30 cGy based on a median follow-up time of 7.5 years
[46]. Another recent study included 22 patients with
stage IE and IIE gastric MALT lymphoma, including 8
cases with t(11;18)(q21;q21) translocation. All patients
reached complete remission after radiation with 30 cGy
without severe toxicity. The overall and 5-year relapse-
free survival rates were 91 and 84 %, respectively at a
median follow-up time of 74 months [47, 48]. The side
effects of radiation are usually transient and tolerable,
including nausea, anorexia and vomiting. Low-dosage ra-
diation therapy preserves the function of the stomach
and avoids nutritional disease induced by surgical resec-
tion. Surgical intervention is preserved only for those
patients with ulcers, acute bleeding and/or perforation.
Systematic chemotherapy should be considered only for
those patients with advanced-stage disease with involve-
ment of distant lymph nodes and/or bone marrow and
those patients with large B-cell transformation. It was re-
ported recently that 95 % of MALT lymphoma patients
who failed in H. pylori eradication antibiotics therapy
showed 95 % complete remission after combined chlor-
ambucil and rituximab therapy, which was superior to
single-drug chemotherapy with chlorambucil or rituximab
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phamide, Hydroxydaunorubicin (adriamycin), Oncovin
(vincristine) and Prednisone] is recommended as a stand-
ard protocol for gastric large B-cell lymphoma [52].
Conclusions
H. pylori gastritis is one of the most common infectious
diseases in China and worldwide. Gastric MALT lymph-
oma is a neoplasm associated with H. pylori infection
and is the first malignant disease that can be cured by
antibiotics therapy alone. The pathogenesis of gastric
MALT lymphoma is not yet elucidated. The estimated
incidence of gastric MALT lymphoma is low (0.3-0.4/
100,000) in the United States and Europe, but the inci-
dence is not known in China. The diagnosis of gastric
MALT lymphoma can be challenging. Due to its rarity,
most general pathologists may not be familiar with the
diagnostic features of gastric MALT lymphoma. There-
fore, underdiagnosis or overdiagnosis of this disease is
not uncommon. Combined hematoxylin and eosin stain-
ing and immunohistochemical staining are routinely
used for the pathologic diagnosis of the lymphoma. Spe-
cial studies, such as molecular studies, are required to
reach a definitive diagnosis in difficult cases. Expert con-
sultation by hematopathologists may be beneficial for
diagnosis. The H. pylori eradication regimen for early-
stage gastric MALT lymphoma is similar to H. pylori
gastritis. However, over-therapy, such as systemic
chemotherapy for early-stage gastric MALT lymphoma,
is not uncommon in the developing world, such as in
China. H. pylori reinfection is common after eradication
therapy due to cross-infection through person-to-person
contact, especially among family members. Communica-
tion between gastroenterologists and oncologists is
advised for the proper management of patients with
gastric MALT lymphoma.
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